-
1
The IHS recommends oral triptans as first-line therapy for acute migraine treatment, while the ACP suggests combining triptans with NSAIDs or acetaminophen.
-
2
Gepants are effective for patients who cannot tolerate triptans or are at risk for medication overuse headache, as they do not cause this complication.
-
3
Preventive therapy choice for migraines should consider patient-specific factors, as comparative evidence among treatments is limited and often of low quality.
-
4
CGRP-targeting therapies offer faster response times for migraine prevention but come with significantly higher costs compared to traditional oral medications.
-
5
Management strategies should be patient-centered, addressing modifiable risk factors and informed by individual clinical variables and treatment history.
Original Source(s)
IHS, ACP Differ on Migraine Tx
-
by Kathryn Wighton
April 14, 2026
Related Content
FDA Signals New Testosterone Pathway
Agency invites sponsors to pursue low libido indication
April 16, 2026
-
2 min
Mandatory Training Modules Deserve a Harder Look
A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.
by Kerri Miller
April 16, 2026
-
3 min
Spectroscopy Roundup: Rover Dogs and Raman Vision
Semi-autonomous robots showcase the future of planetary exploration, as spectroscopy also reshapes lab-on-chip biology and microplastics research
April 14, 2026
-
5 min